Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

1.27
+0.04003.25%
Post-market: 1.290.0200+1.57%19:30 EDT
Volume:275.82K
Turnover:346.30K
Market Cap:30.39M
PE:-1.43
High:1.34
Open:1.22
Low:1.18
Close:1.23
52wk High:9.22
52wk Low:0.9000
Shares:23.93M
Float Shares:8.60M
Volume Ratio:0.83
T/O Rate:3.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8859
EPS(LYR):-1.0574
ROE:-553.75%
ROA:-213.40%
PB:30.72
PE(LYR):-1.20

Loading ...

Company Profile

Company Name:
Actuate Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
- -
Office Location:
1751 River Run,Suite 400,Fort Worth,Texas,United States
Zip Code:
76107
Fax:
- -
Introduction:
Actuate Therapeutics, Inc. is a Delaware corporation founded on January 16, 2015. It is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through inhibition of glycogen synthase kinase-3 (GSK-3). The company is developing elraglusib (formerly 9-ING-41), a small molecule designed to enter cancer cells and block the function of the GSK-3β enzyme—a master regulator of complex biological signaling cascades, including oncogene-mediated cascades that drive tumor cell survival, growth, migration, and invasion.

Directors

Name
Position
Daniel M. Schmitt
President, Chief Executive Officer and Director
Aaron G.L. Fletcher
Chairperson and Director
Amy Ronneberg
Director
Dan Zabrowski
Director
Jason Keyes
Director
Les Kreis, Jr.
Director
Roger Sawhney
Director
Todd Thomson
Director

Shareholders

Name
Position
Daniel M. Schmitt
President, Chief Executive Officer and Director
Andrew P. Mazar
Chief Operating Officer
Paul Lytle
Chief Financial Officer